Clinical trial · Interventional
Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids
The Evaluation About the Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids
NCT01434524CI-TRIAL-00005491completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The long-term outcomes of branched-chain amino acid (BCAA) administration in patients undergoing hepatic resection remain unclear. The aim of this study is to assess the impact of oral supplementation with BCAA on the prevention for the development of liver tumorigenesis in patients undergoing liver resection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LIVACT | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Control
- description
- normal dietary
- type
- NO_INTERVENTION
- label
- LIVACT
- description
- The present study used LIVACT for preoperative supplementation, commencing two weeks prior to surgery, and continuing for at least 6 months postoperatively with careful monitoring of compliance.
- interventionNames
- Drug: LIVACT
Primary outcomes (1)
- measure
- Postoperative tumor recurrence rate
- timeFrame
- 5 years follow up
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * These patients were scheduled for elective liver resection to treat hepatocellular carcinoma or adenocarcinoma of the liver. Exclusion Criteria: * a body-weight loss greater than 10% during the 6 months prior to surgery, * the presence of distant metastases, or * serious impairment of organ function due to respiratory, renal, or heart disease.
References
Publications (0)
Data not yet available
No reference posted for this study.